Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab vs placebo in psoriatic arthritis with inadequate response/intolerance to one anti-TNFα agent
2023-504715-33-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Guselkumab with Placebo (2 arms). Primary endpoint: ACR20 response at Week 24. Started Apr 2024; status: completed.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2023-504715-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504715-33-00.